ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "fractures"

  • Abstract Number: 1232 • 2016 ACR/ARHP Annual Meeting

    Interdisciplinary Osteoporosis Clinical Working Group and Fracture Liaison Service at Loma Linda University Medical Center (LLUMC): Laying the Groundwork

    Karina Marianne D. Torralba1, Micah Yu2, Cong-Bin Wang3, Kevin A. Codorniz4, James P. Larsen3, Silvana M Giannelli5, Vaneet Sandhu6, Nasim Daoud7 and Gary D. Botimer3, 1Rheumatology, Loma Linda University, Loma Linda, CA, 2Internal Medicine, Loma Linda University Medical Center, Loma Linda, CA, 3Loma Linda University Medical Center, Loma Linda, CA, 4Loma Linda University University Medical Center, Loma Linda, CA, 5Division of Endocrinology, Loma Linda University, Loma Linda, CA, 6Division of Rheumatology, Loma Linda University, Loma Linda, CA, 7Division of Rheumatology, Loma Linda University Medical Center, Loma Linda, CA

    Background/Purpose:  There is an ongoing effort worldwide to effect quality improvement to address secondary prevention of fractures. Patients who have incurred fractures attributed to osteoporosis…
  • Abstract Number: 1796 • 2016 ACR/ARHP Annual Meeting

    Osteoporosis and Vertebral Fractures in Patients with Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis

    Mario García-Carrasco1,2, Pamela Soto-Santillan3, Samanda Adriana Rojas villarraga4, Nicolás Molano-González5 and Claudia Mendoza Pinto6, 1Systemic Autoimmune Diseases Research Unit, HGR 36-CIBIOR Instituto Mexicano del Seguro Social, Puebla, Mexico, 2Inmunología y Reumatología, Universidad Autónoma de Puebla, Puebla, Mexico, 3Internal Medicine, Systemic Autoimmune Diseases Research Unit, IMSS, Puebla, México, Puebla, Mexico, 4Novartis de Colombia, Bogota, Colombia, 5Center for Autoimmune Diseases Research (CREA). School of Medicine and Health Sciences, Universidad del Rosario, Bogotá, Colombia., Bogota, Colombia, 6Systemic Autoimmune Diseases Research Unit, HGR 36-CIBIOR, IMSS, Puebla, Mexico

    Background/Purpose: Observational studies have indicated a high but heterogeneous prevalence of low bone mineral density (BMD) and vertebral fractures (FV) in patients with systemic lupus…
  • Abstract Number: 21 • 2016 ACR/ARHP Annual Meeting

    Outcomes of Rheumatoid Arthritis Patients with Hip Fracture

    Lucy Liu1, Joan Lo2 and Malini Chandra3, 1Internal Medicine, Kaiser Permanente, Oakland, CA, 2Endocrinology, Kaiser Permanente, Oakland, CA, 3Kaiser Permanente, Oakland, CA

    Background/Purpose:  Rheumatoid arthritis (RA) is a well-known risk factor for osteoporosis and hip fracture. Recent studies suggest RA patients fracture at a younger age and…
  • Abstract Number: 334 • 2016 ACR/ARHP Annual Meeting

    Predictors of Fragility Fractures in Patients with Rheumatoid Arthritis Not on Steroids: An Observational Study

    Sarah Dyball1 and Marwan Bukhari2, 1University Hospital South Manchester, Manchester, United Kingdom, 2Royal Lancaster Infirmary, Lancaster, United Kingdom

    Background/Purpose:   Patients with rheumatoid arthritis (RA) have an increased fracture risk, however, this is confounded by a coexisting use of steroids. This study aims…
  • Abstract Number: 336 • 2016 ACR/ARHP Annual Meeting

    The Risk of Subsequent Osteoporotic Fractures Is Decreased in Patients Experiencing Fracture While on Denosumab

    DL Kendler1, A Chines2, ML Brandi3, S Papapoulos4, EM Lewiecki5, J-Y Reginster6, C Roux7, M Munoz Torres8, A Wang2 and HG Bone9, 1University of British Columbia, Vancouver, BC, Canada, 2Amgen Inc., Thousand Oaks, CA, 3University of Florence, Florence, Italy, 4Leiden University Medical Center, Leiden, Netherlands, 5New Mexico Clinical Research & Osteoporosis Center, Albuquerque, NM, 6University of Liège, Liège, Belgium, 7Paris Descartes University, Paris, France, 8Hospital Universitario San Cecilio, Granada, Spain, 9Michigan Bone and Mineral Clinic, Detroit, MI

    Background/Purpose:  Osteoporosis is a common, progressive condition leading to increased bone fragility and susceptibility to fracture.  Although osteoporosis therapy decreases fracture risk, fractures while on…
  • Abstract Number: 346 • 2015 ACR/ARHP Annual Meeting

    Autoantibodies to Osteoprotegerin Are Independently Associated with Low Hip Bone Mineral Density and Increased Fractures in Axial Spondyloarthritis

    Sizheng Zhao1,2, Barbara Hauser3, Micaela Visconti3, Philip L. Riches3, Stuart H. Ralston3 and Nicola Goodson1,2, 1Musculoskeletal Biology I, Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, United Kingdom, 2Department of Rheumatology, Aintree University Hospital, Liverpool, United Kingdom, 3Centre for Genomic and Experimental Medicine, Western General Hospital, Edinburgh, United Kingdom

    Background/Purpose: Axial spondyloarthritis (axSpA) is associated with osteoporosis. However the underlying causes are incompletely understood. Osteoprotegerin (OPG) is a bone protective protein that acts as…
  • Abstract Number: 371 • 2015 ACR/ARHP Annual Meeting

    New Vertebral Fractures after Vertebroplasty: Two Year Results from a Randomised Placebo-Controlled Trial

    Margaret P. Staples1, B Matthew Howe2, Michael Ringler2, Peter Mitchell3, Chris Wriedt4, John Wark5, Peter Ebeling6, Richard Osborne7, David Kallmes2 and Rachelle Buchbinder8, 1Monash Department of Clinical Epidemiology, Cabrini Institute and Monash University, Malvern, Australia, 2Department of Radiology, Mayo Clinic College of Medicine, Rochester, MN, 3Department of Radiology, The University of Melbourne, Royal Melbourne Hospital, Melbourne, Australia, 4MIA Radiology, Melbourne, Australia, 5Department of Medicine, The University of Melbourne, Royal Melbourne Hospital, Melbourne, Australia, 6Department of Medicine, Monash University, Monash Medical Centre, Melbourne, Australia, 7Public Health Innovation, Deakin University, Melbourne, Australia, 8Monash Department of Clinical Epidemiology, Cabrini Institute and Monash University, Melbourne, Australia

    Background/Purpose: We previously reported the results of a randomized participant and outcome assessor blinded controlled trial that found no beneficial effect of vertebroplasty (VP) over…
  • Abstract Number: 382 • 2015 ACR/ARHP Annual Meeting

    Twelve Months after Osteoporosis Associated Fracture – Has Adequate Therapy Been Initiated?

    Christoph Hemmeler1, Sabrina Morell2, Paul Hasler1 and Thomas Gross2, 1Rheumatology, Kantonsspital Aarau, Aarau, Switzerland, 2Traumatology, Kantonsspital Aarau, Aarau, Switzerland

    Background/Purpose: Evidence shows that of ten patients taking medication against osteoporosis one will avoid subsequent fractures, decreasing the risk by > 50 %. On the…
  • Abstract Number: 2084 • 2015 ACR/ARHP Annual Meeting

    Dendritic Cell-Specific Transmembrane Protein (DC-STAMP) Modulates Bone Resorption in Inflammatory Arthritis and Fracture Repair

    Yahui Grace Chiu1, Tzong-Ren Sheu2, Jinbo Li3, Dongge Li4, Michael Thullen2, Brendan Boyce5, Christopher T. Ritchlin6 and Javier Rangel-Moreno7, 1Allergy, Immunology, and Rheumatology, University of Rochester, Rochester, NY, 2Center for Musculoskeletal Research, University of Rochester, Rochester, NY, 3Pathology, University of Rochester, Rochester, NY, 4Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY, 5University of Rochester, Rochester, NY, 6Allergy, Immunology and Rheumatololgy Division, University of Rochester Medical Center, Rochester, NY, 7Allergy, Immunology & Rheumatology, University of Rochester, Rochester, NY

    Background/Purpose: Osteoclasts (OC) direct pathologic bone resorption in osteoporosis and inflammatory arthritis. We previously demonstrated that DC-STAMP (Dendritic Cell-Specific Transmembrane protein), a 7-pass transmembrane protein,…
  • Abstract Number: 2165 • 2015 ACR/ARHP Annual Meeting

    Awareness and Reasons for Lack of Post-Fracture Osteoporosis Therapy: A Survey of Post-Menopausal Women

    Denise Boudreau1, Onchee Yu1, Akhila Balasubramanian2, Jane Grafton1, Heidi Wirtz3, Andreas Grauer3, D. Barry Crittenden3 and Delia Scholes1, 1Group Health Research Institute, Seattle, WA, 2Center for Observational Research, Amgen, Inc., Thousand Oaks, CA, 3Amgen Inc., Thousand Oaks, CA

    Background/Purpose: Osteoporotic fractures cause patient morbidity and increase risk for future fracture. Effective drug therapies for osteoporosis (OP) are available, yet only a minority of…
  • Abstract Number: 2210 • 2015 ACR/ARHP Annual Meeting

    Immunological Dysregulation and Inadequate Hypoxia Adaptation – HIF-Stabilization As Possible Prevention of Fracture Healing Disorders in RA or Immune-Suppressed Patients

    Annemarie Lang1,2,3, Sarah Fuegener2, Paula Hoff1,2, Katharina Schmidt-Bleek4, Timo Gaber1,2 and Frank Buttgereit2, 1German Rheumatism Research Center (DRFZ), Berlin, Germany, 2Department of Rheumatology and Clinical Immunology, Charité University Medicine, Berlin, Germany, 3Berlin-Brandenburg School of Regenerative Therapies (BSRT), Berlin, Germany, 4Julius Wolff Institut, Charité University Medicine, Berlin, Germany

    Background/Purpose: Patients suffering from rheumatoid arthritis (RA) are often affected by fracture-healing complications such as increased fracture healing time or non-unions. There is not much…
  • Abstract Number: 3173 • 2015 ACR/ARHP Annual Meeting

    Premature Mortality Due to Fractures in a Population-Based Prospective Cohort Study of 238,673 Older Women and Men

    Lyn March1, Weiwen Chen2, Judy M Simpson3, Fiona Blyth4 and Jacqueline Center2, 1Department of Rheumatology, Northern Clinical School, Institute of Bone and Joint Research, Kolling Institute, University of Sydney & Department of Rheumatology, Royal North Shore Hospital, St Leonards, Sydney, Australia, 2Endocrinology, Osteoporosis & Bone Biology Garvan Institute of Medical Research, St Vincent's Clinical School, UNSW, Darlinghurst, Australia, 3Statistics, University of Sydney School of Public Health, Sydney, Australia, 4Concord Clinical School University of Sydney and Sax Institute, Sydney, Australia

    Background/Purpose: Osteoporotic (OP) fractures and falls are a growing global problem as the population ages. One third of all falls related deaths are attributable to…
  • Abstract Number: 2268 • 2014 ACR/ARHP Annual Meeting

    Odanacatib Anti-Fracture Efficacy and Safety in Postmenopausal Women with Osteoporosis: Results from the Phase III Long-Term Odanacatib Fracture Trial

    Michael R. McClung1, Bente Langdahl2, Socrates Papapoulos3, Kenneth G. Saag4, Silvano Adami5, Henry G. Bone6, Tobias de Villiers7, Douglas P. Kiel8, Annie Kung9, Prasanna Kumar10, Sung-Kil Lim11, Xu Ling12, Kurt Lippuner13, Carlos Mautalen14, Toshitaka Nakamura15, Jean-Yves Reginster16, Ian R. Reid17, José Adolfo Rodríguez-Portales18, Christian Roux19, Jesus Walliser20, Nelson B. Watts21, José R. Zanchetta22, Cristiano A.F. Zerbini23, Andrea Rybak-Feiglin24, Dosinda Cohn24, Carolyn A. DaSilva24, Rachid Massaad25, Arthur Santora24, Boyd B. Scott24, Nadia Verbruggen25, Albert Leung26 and Antonio Lombardi24, 1Oregon Osteoporosis Center, Portland, OR, 2Aarhus University Hospital, Aarhus, Denmark, 3Leiden University Medical Center, Leiden, Netherlands, 4Immunology & Rheumatology, The University of Alabama at Birmingham, Birmingham, AL, 5Rheumatology Department, University of Verona, Verona, Italy, 6Michigan Bone and Mineral Clinic, Detroit, MI, 7Stellenbosch University, Stellenbosch, South Africa, 8Institute for Aging Research, Hebrew Senior Life, Harvard Medical School, Boston, MA, 9University of Hong Kong, Pokfulam, Hong Kong, China, 10Bangalore Diabetes Centre, Bangalore, India, 11Yonsei University, Seoul, South Korea, 12Peking Union Medical College Hospital, Beijing, China, 13Bern University Hospital, Bern, Switzerland, 14Centro de Osteopatías Médicas, Buenos Aires, Argentina, 15University of Occupational & Environmental Health, Fukuoaka, Japan, 16CHU-Centre Ville, Policliniques BRULL, Liege, Belgium, 17Department of Medicine, University of Auckland, Auckland, New Zealand, 18Pontificia Universidad Católica de Chile, Santiago, Chile, 19Paris Descartes University, Cochin Hospital, Paris, France, 20Bone Metabolism Clinic, Hospital Angeles del Pedregal, Mexico City, Mexico, 21Mercy Health Osteoporosis and Bone Health Services, Cincinnati, OH, 22IDIM Instituto de Investigaciones Metabolicas, Buenos Aires, Argentina, 23Centro Paulista de Investigações Clinicas, São Paulo, Brazil, 24Merck Sharp and Dohme Corp., Rahway, NJ, 25MSD Europe Inc., Brussels, Belgium, 26Clinical Research, Merck Sharp and Dohme Corp., Rahway, NJ

    Background/Purpose: Odanacatib (ODN), a selective oral inhibitor of cathepsin K, is in development for the treatment of osteoporosis. The Phase III Long-Term Odanacatib Fracture Trial…
  • Abstract Number: 2106 • 2014 ACR/ARHP Annual Meeting

    Surgical Compared with Nonsurgical Management of Fractures in Men with Chronic Spinal Cord Injury

    Monique Bethel1, Lauren Bailey2, Frances Weaver2, Brian Le3, Stephen Burns4, Jelena Svircev4, Michael Heggeness5 and Laura Carbone6, 1Internal Medicine, Georgia Regents University, Augusta, GA, 2Edward Hines Jr. VA Hospital, Chicago, IL, 3Medicine, Georgia Regents University, Augusta, GA, 4VA Puget Sound Healthcare System, Seattle, WA, 5Orthopaedic Surgery, University of Kansas School of Medicine, Kansas City, KS, 6Medicine, Charlie Norwood VA Medical Center, Augusta, GA

    Background/Purpose: Patients with a chronic spinal cord injury (SCI) develop osteoporosis and are at high risk for fracture.  However, there is limited information on how…
  • Abstract Number: 1835 • 2014 ACR/ARHP Annual Meeting

    Anti-Osteoporosis Medication Use after Hip or Vertebral Fracture

    Robert A. Overman1 and Chad L. Deal2, 1Eshelman School of Pharmacy - Division of Pharmaceutical Policy and Outcomes, University of North Carolina, Chapel Hill, NC, 2Dept of Rheum & Imm Dis /A 50, Cleveland Clinic, Cleveland, OH

    Background/Purpose: Current National Osteoporosis Guidelines recommend treatment with an approved osteoporosis medication after hip and vertebral fracture. Only 20% of patients receive osteoporosis therapy after…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology